Cargando…

Type I Interferons and Natural Killer Cell Regulation in Cancer

Type I interferons (IFNs) are known to mediate antitumor effects against several tumor types and have therefore been commonly used in clinical anticancer treatment. However, how IFN signaling exerts its beneficial effects is only partially understood. The clinically relevant activity of type I IFNs...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Lena, Aigner, Petra, Stoiber, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374157/
https://www.ncbi.nlm.nih.gov/pubmed/28408907
http://dx.doi.org/10.3389/fimmu.2017.00304
_version_ 1782518841195102208
author Müller, Lena
Aigner, Petra
Stoiber, Dagmar
author_facet Müller, Lena
Aigner, Petra
Stoiber, Dagmar
author_sort Müller, Lena
collection PubMed
description Type I interferons (IFNs) are known to mediate antitumor effects against several tumor types and have therefore been commonly used in clinical anticancer treatment. However, how IFN signaling exerts its beneficial effects is only partially understood. The clinically relevant activity of type I IFNs has been mainly attributed to their role in tumor immune surveillance. Different mechanisms have been postulated to explain how type I IFNs stimulate the immune system. On the one hand, they modulate innate immune cell subsets such as natural killer (NK) cells. On the other hand, type I IFNs also influence adaptive immune responses. Here, we review evidence for the impact of type I IFNs on immune surveillance against cancer and highlight the role of NK cells therein.
format Online
Article
Text
id pubmed-5374157
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-53741572017-04-13 Type I Interferons and Natural Killer Cell Regulation in Cancer Müller, Lena Aigner, Petra Stoiber, Dagmar Front Immunol Immunology Type I interferons (IFNs) are known to mediate antitumor effects against several tumor types and have therefore been commonly used in clinical anticancer treatment. However, how IFN signaling exerts its beneficial effects is only partially understood. The clinically relevant activity of type I IFNs has been mainly attributed to their role in tumor immune surveillance. Different mechanisms have been postulated to explain how type I IFNs stimulate the immune system. On the one hand, they modulate innate immune cell subsets such as natural killer (NK) cells. On the other hand, type I IFNs also influence adaptive immune responses. Here, we review evidence for the impact of type I IFNs on immune surveillance against cancer and highlight the role of NK cells therein. Frontiers Media S.A. 2017-03-31 /pmc/articles/PMC5374157/ /pubmed/28408907 http://dx.doi.org/10.3389/fimmu.2017.00304 Text en Copyright © 2017 Müller, Aigner and Stoiber. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Müller, Lena
Aigner, Petra
Stoiber, Dagmar
Type I Interferons and Natural Killer Cell Regulation in Cancer
title Type I Interferons and Natural Killer Cell Regulation in Cancer
title_full Type I Interferons and Natural Killer Cell Regulation in Cancer
title_fullStr Type I Interferons and Natural Killer Cell Regulation in Cancer
title_full_unstemmed Type I Interferons and Natural Killer Cell Regulation in Cancer
title_short Type I Interferons and Natural Killer Cell Regulation in Cancer
title_sort type i interferons and natural killer cell regulation in cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374157/
https://www.ncbi.nlm.nih.gov/pubmed/28408907
http://dx.doi.org/10.3389/fimmu.2017.00304
work_keys_str_mv AT mullerlena typeiinterferonsandnaturalkillercellregulationincancer
AT aignerpetra typeiinterferonsandnaturalkillercellregulationincancer
AT stoiberdagmar typeiinterferonsandnaturalkillercellregulationincancer